Pharmaceuticals and Life Sciences Pharmaceuticals and Life Sciences

Medici Technologies Inc. (dba Livewell) in its sale to Hims & Hers

On December 4, 2025, Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform in the United States, announced its expansion into Canada through its acquisition of Medici Technologies Inc. (dba Livewell). Livewell is a trusted Canadian digital health platform focused...

Lead Office: Montreal Date Announced: December 4, 2025 Value: --

Morphocell Technologies Inc. in its completion of US$50-million Series A

On December 2, 2025, Morphocell Technologies Inc. announced it completed US$50-million Series A financing following a US$10-million add-on led by Investissement Québec. Morphocell Technologies Inc. is a biotechnology company. Osler, Hoskin & Harcourt LLP advised Morphocell Technologies...

Lead Office: Montreal Date Announced: December 2, 2025 Value: US$50 million

Mind Medicine in its $249-million underwritten public offering

On November 3, 2025, Mind Medicine, a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced it closed approximately a $249-million underwritten public offering which includes a full exercise of the underwriter’s option to purchase...

Lead Office: Vancouver Date Announced: November 3, 2025 Value: $249 million

AmacaThera in its licensing agreement with Pacira Biosciences for US$230 million

On November 4, 2025, AmacaThera announced that it signed an exclusive global licensing agreement with Pacira Biosciences for up to US$230 million, validating its tunable drug delivery platform. AmacaThera is a leading developer of next-generation hydrogel-based drug delivery solutions. Using a...

Lead Office: Toronto Date Announced: November 4, 2025 Value: US$230 million

Genesys Capital in connection with Antegrade Medical’s $7.3-million Series Seed financing

On October 28, 2025,  Antegrade Medical Inc. announced the closing of a $7.3-million Series Seed financing. The financing was led by Sectoral Asset Management and had participation from Genesys Capital, Desjardins Capital, Seido Capital and private investors. Genesys Capital invests in and...

Lead Office: Toronto Date Announced: October 28, 2025 Value: $7.3 million

Aspect Biosystems in its $115-million Series B funding round

On January 8, 2025, Aspect Biosystems announced the closing of its $115-million Series B funding round led by Dimension, with participation from existing and new investors including Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures, Pangaea...

Lead Office: Vancouver Date Announced: January 8, 2025 Value: $115 million

Amplitude Ventures and Lifearc Ventures in connection with Fluid Biomed's $27-million financing

On December 16, 2024, Fluid Biomed announced the close of its $27-million Series A funding round co-led by Amplitude Ventures and an undisclosed investor, with follow-up investment from LifeArc Ventures. Fluid Biomed plans to use the funds to fuel the development of its innovative stent for brain...

Lead Office: Calgary Date Announced: December 16, 2024 Value: $27 million

KisoJi in its raising of $57-million Series B financing

On December 6, 2024, KisoJi announced it raised $57 million of Series B financing. This round was co-led by Investissement Québec and Lumira Ventures. The round also saw participation from Fonds de solidarité FTQ, adMare BioInnovations and Remiges Ventures. The company plans on utilizing the...

Lead Office: Montreal Date Announced: December 6, 2024 Value: $57 million

Ernst & Young as court-appointed monitor to IntelGenx and its sale to Atai

On October 2, 2024, in the context of their successful restructuring proceedings under the Companies’ Creditors Arrangement Act, IntelGenx Corp. and IntelGenx Technologies Corp. (together, IntelGenx) entered into a transaction with Atai Life Sciences AG (Atai) whereby Atai acquired all of the...

Lead Office: Montreal Date Announced: October 2, 2024 Value: --

Nomic Bio in its raising of $42 million in a Series B financing round

On September 17, 2024, Nomic Bio announced its closing of a $42-million Series B financing round. This round was led by a U.S.-based life-sciences-focused investor and also saw participation from Amplitude Ventures, AVANT BIO, Lux Capital, Real Ventures and SR One. Through this funding, the...

Lead Office: Toronto Date Announced: September 17, 2024 Value: $42 million